Joshi Alumkal, M.D., was awarded a $1.1M NCI Beau Biden Cancer Moonshot Drug Resistance and Sensitivity Network P50 Supplement for “Clarifying the Role of LSD1 in Neuroendocrine Prostate Cancer.” The P50 Prostate SPORE is led by Arul Chinnaiyan, M.D., Ph.D., and Ganesh Palapattu, M.D.